| Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion‐dependent thalassemia: a literature review TE Delea, J Edelsberg, O Sofrygin, SK Thomas, JF Baladi, PD Phatak, ... Transfusion 47 (10), 1919-1929, 2007 | 233 | 2007 |
| Causal inference for social network data EL Ogburn, O Sofrygin, I Diaz, MJ Van der Laan Journal of the American Statistical Association 119 (545), 597-611, 2024 | 135 | 2024 |
| Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system … TE Delea, O Sofrygin, SK Thomas, JF Baladi, PD Phatak, TD Coates Pharmacoeconomics 25, 329-342, 2007 | 113 | 2007 |
| Semi-parametric estimation and inference for the mean outcome of the single time-point intervention in a causally connected population O Sofrygin, MJ van der Laan Journal of causal inference 5 (1), 20160003, 2017 | 67 | 2017 |
| Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-α antagonists M Vera-Llonch, E Massarotti, F Wolfe, N Shadick, R Westhovens, ... The Journal of Rheumatology 35 (9), 1745-1753, 2008 | 56 | 2008 |
| Child wasting and concurrent stunting in low-and middle-income countries A Mertens, J Benjamin-Chung, JM Colford Jr, AE Hubbard, ... Nature 621 (7979), 558-567, 2023 | 52 | 2023 |
| Cost–effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate M Vera-Llonch, E Massarotti, F Wolfe, N Shadick, R Westhovens, ... Rheumatology 47 (4), 535-541, 2008 | 48 | 2008 |
| Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases D Weycker, O Sofrygin, K Seefeld, RG Deeter, J Legg, J Edelsberg BMC Health Services Research 13, 1-10, 2013 | 47 | 2013 |
| Early-childhood linear growth faltering in low-and middle-income countries J Benjamin-Chung, A Mertens, JM Colford Jr, AE Hubbard, ... Nature 621 (7979), 550-557, 2023 | 46* | 2023 |
| Sequential double robustness in right-censored longitudinal models AR Luedtke, O Sofrygin, MJ van der Laan, M Carone arXiv preprint arXiv:1705.02459, 2017 | 44 | 2017 |
| Robust and flexible estimation of stochastic mediation effects: a proposed method and example in a randomized trial setting KE Rudolph, O Sofrygin, W Zheng, MJ Van Der Laan Epidemiologic methods 7 (1), 20170007, 2018 | 43 | 2018 |
| Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective TE Delea, K El-Ouagari, J Karnon, O Sofrygin Breast cancer research and treatment 108, 375-387, 2008 | 41 | 2008 |
| sl3: Modern pipelines for machine learning and Super Learning JR Coyle, NS Hejazi, I Malenica, RV Phillips, O Sofrygin R package version 1 (2), 2021 | 40 | 2021 |
| Mediation of neighborhood effects on adolescent substance use by the school and peer environments KE Rudolph, O Sofrygin, NM Schmidt, R Crowder, MM Glymour, J Ahern, ... Epidemiology 29 (4), 590-598, 2018 | 38 | 2018 |
| Targeted learning with daily EHR data O Sofrygin, Z Zhu, JA Schmittdiel, AS Adams, RW Grant, MJ van der Laan, ... Statistics in medicine 38 (16), 3073-3090, 2019 | 37 | 2019 |
| Causes and consequences of child growth failure in low-and middle-income countries A Mertens, J Benjamin-Chung, JM Colford Jr, J Coyle, MJ van der Laan, ... MedRxiv, 2020.06. 09.20127100, 2020 | 34 | 2020 |
| Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria TE Delea, O Sofrygin, JL Palmer, H Lau, VC Munk, J Sung, A Charney, ... Journal of the American Society of Nephrology 20 (10), 2205-2213, 2009 | 34 | 2009 |
| Use of machine learning to develop a risk-stratification tool for emergency department patients with acute heart failure DR Sax, DG Mark, J Huang, O Sofrygin, JS Rana, SP Collins, AB Storrow, ... Annals of Emergency Medicine 77 (2), 237-248, 2021 | 33 | 2021 |
| Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab TE Delea, P Tappenden, O Sofrygin, D Browning, MM Amonkar, J Karnon, ... The European Journal of Health Economics 13, 589-603, 2012 | 32 | 2012 |
| Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective M Vera-Llonch, E Dukes, J Rejas, O Sofrygin, M Mychaskiw, G Oster The European Journal of Health Economics 11, 35-44, 2010 | 27 | 2010 |
